

What does Serrapeptase enzyme do?

Dead and inflamed tissue are two of the key causes of the majority of ailments in the body. Serrapeptase digests (dissolves) non-living tissue, blood clots, cysts, and arterial plaque and all inflamed tissue which is then dispersed.

There is a growing list of conditions that respond to Serrapeptase simply taken orally in tablet or capsule form.

- Arthritis
- Fibrocystic breast disease
- Carpal tunnel syndrome
- Atherosclerosis
- MS
- Traumatic injury (e.g. sprains and torn ligaments)
- Post-operative inflammation
- Head-aches, migraines caused by inflammation
- To support various treatments of infections
- Cystitis
- Bronchial Asthma
- Eye Problems:
 - Inflammation
 - Blocked veins etc
- ENT problems:
 - Sinusitis problems
 - Chronic ear infections
 - Runny nose etc

And what is more, in over 25 years of studies and usage no harmful side effects have been found.

The Safe Enzyme Alternative

The search for a superior enzyme that offers safe but powerful anti-inflammatory properties, thus averting the terrible side effects, ended when Serratia peptidase (Serrapeptase) enzyme was

discovered in the early 70's. Serrapeptase is now in wide clinical use throughout Europe and Asia as a viable alternative to salicylates, ibuprofen (sold as an OTC in the U.S.) and the more potent NSAIDs. Serrapeptase is an anti-inflammatory, proteolytic enzyme isolated from the microorganism, Serratia E15 and has no inhibitory effects on prostaglandins, is devoid of gastrointestinal side effects and offers a sensible alternative.

Serrapeptase the Enzyme

Serrapeptase is processed commercially in the laboratory through fermentation. It was originally found in the silkworm. The silkworm has a special relationship with the Serratia E15 microorganisms in its intestines. The enzymes secreted by the bacteria in silkworm intestines have the ability to dissolve avital tissue, but have no detrimental effect on the host's living cells. Thus by dissolving the silkworm's protective cocoon (avital tissue), the winged creature is able to emerge and fly away.

Serrapeptase References:

- 1) Kee WH, Tan SL, Lee V, Salmon YM. The treatment of breast engorgement with Serrapeptase: a randomised double blind controlled trial. Singapore Med J. 1989;30(1): 48-54.
- 2) Mizukoshi, D. et al. A double blind clinical study of Serrapeptase in the treatment of chronic sinusitis. Igaku Ayrni 109:50-62.1979.
- 3) Carratu, L. et al. Physio-chemical and rheological research on mucolytic activity of Serrapeptase in chronic broncho-pneumopathies. Curr. Ther. Res. 28(6): 937-951. 1980.
- 4) Braga, P.C. et al. Effects of Serrapeptase on muco-ciliary clearance in patients with chronic bronchitis. Curr. Ther. Res. 29(5): 738-744,1981.
- 5) Mazzonie, A. et al. Evaluation of Serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double blind randomised trial versus placebo. J. Int. Med. Res. 18(5): 379-388,1990.
- 6) Kakinumu, A. et al. Regression of fibrinolysis in scalded rats by administration of Serrapeptase. Biochem. Pharmacol. 31:2861-2866,1982.

7) Marly, M. Enzymotherapie anti-inflammatoire a l'aide de la Serrapeptase: resultats cliniques en traumatologie et en ORL. C RTherapeut. 3:9-19,1985.

8) Odagiri, J. et al. Clinical applications of Serrapeptase in sinusitis. Med. Consult. New Remedy 6:201-209, 1979.

9) Yamazaki, J. et al. Anti-inflammatory activity of Serrapeptase, a protease produced by a strain of Serratia. Folia Pharmacol. Japon. 6^302-314,1967.

10) Harad, Y. Clinical efficacy of Serrapeptase on buccal swelling after radical operation for chronic sinusitis. Igaku Ayumi 123:768-778.1982.

11) Matsudo, A. et al. Effect of Serrapeptase on inflammatory oedema following operation for thyroid disease. Med. Consult. New Remedy 18:171-175, 1981.

12) Fujitani, T. et al. Effect of anti-inflammatory agent on transfer of antibiotics to the maxillary sinus mucosa in chronic sinusitis. Otorhinolaryngol. Clin. North Am. 66:557-565. 1976.

13) Tago, T. and Mitsui, S. Effects of Serrapeptase in dissolution of sputum, especially in patients with bronchial asthma. Jap. Clin. Exp. Med. 49:222-228, 1972.

14) Mazzonie, A. et al. Evaluation of Serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double blind randomised trial versus placebo. J. int. Med. Res. 18(5): 379-388,1990.

15) Kase, Y. et al. A new method for evaluating mucolytic expectorant activity and its application. II. Application to two proteolytic enzymes, Serrapeptase and seaprose. Arzneimittelforschung 32:374-378,1982.

16) Marriott, C. Modification of the rheological properties of mucus by drugs. Adv. Exp. Med. Biol. 144^75-84, 1982.

17) Majima. Y. et al. Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am. Rev. Respir. Dis. 141:79-83.1990.

18) Miyata, K. Intestinal absorption of Serrapeptase. J ApplBiochem. 1980:2:111-16.

19) Aso T. et al. Breast engorgement and its treatment: Clinical effects of (Serrapeptase) an anti-inflammatory enzyme preparation. The world of Obstetrics and Gynaecology (Japanese). 1981:33:371-9.

20) Esch PM, Gemgross H. Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joints in treatment with Serrapeptase a prospective study (German). FortschrMed. 1989; 107(4): 67-8, 71-2.